• Explore /
  • Poster
  • / A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies.

A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies.

Abstract Poster

Authors

null

Rana R. McKay

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Rana R. McKay , Lillian Werner , Lauren Christine Harshman , Joaquim Bellmunt , Christopher Sweeney , Jonathan E. Rosenberg , Eliezer VanAllen , Meghara K. Walsh , Ulka N. Vaishampayan , David F. McDermott , Toni K. Choueiri

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT01283048

Citation

J Clin Oncol 33, 2015 (suppl; abstr 4559)

DOI

10.1200/jco.2015.33.15_suppl.4559

Abstract #

4559

Poster Bd #

233

Abstract Disclosures

Similar Posters

First Author: Patrick Y. Wen

First Author: Mansoor Raza Mirza

First Author: Cristina Cruz Zambrano

First Author: Sylvie Negrier